Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of HYR-PB21 in Healthy Volunteers
- Conditions
- Acute Postoperative Pain
- Interventions
- Registration Number
- NCT04169256
- Lead Sponsor
- Fruithy Medical Pty Ltd
- Brief Summary
This study is the first time into human study (FTIH) for HYR-PB21 for injection. The study will evaluate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending and single subcutaneous dose of HYR-PB21 for injection in healthy adult volunteers.The results of this study are intended to be used to identify appropriate and well tolerated doses of HYR-PB21 for injection to be used in further studies. A comparison of PK/PD characteristics between HYR-PB21 for injection and EXPAREL will also be included in this study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 32
- Voluntarily provide written informed consent.
- Subjects who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
- Subjects with liver function tests (LFTs) within the reference range, or deemed clinically not significant by the investigator or delegate.
- Male or female (of non-child bearing potential) between 18 and 50 years of age, inclusive.
- If female, be of non-childbearing potential: e.g. post-menopausal for ≥12 consecutive months with follicle stimulating hormone (FSH) ≥40 mIU/mL at Screening; or surgical sterilization for at least 90 days prior to screening e.g., tubal ligation or hysterectomy. Note: Provision of documentation is not required for female sterilization, verbal confirmation is adequate.
- Male patients must be surgically sterile (biologically or surgically) or commit to the use of a reliable method of birth control for the duration of the study until at least 30 days after the administration of study medication.
- Have a body mass index 18-30 kg/m2 (inclusive).
- Blood pressure < 140/90 mmHg at screening and heart rate <100 bpm. One repeat assessment is permitted. Screening laboratory tests that are deemed to be non-clinically significant by the investigator.
- Subjects must not have donated or lost more than 400 mL of blood within 12 weeks of dosing, more than 200mL of blood within 4 weeks of dosing or donated any blood within 2 weeks of dosing.
- Subjects must not donate sperm or egg during study or in 30 days after dosing.
- Be able to understand the study procedures, comply with all study procedures, and agree to participate in the study program.
- Be able to understand and communicate in English.
- History of hypersensitivity or idiosyncratic reactions to amide-type local anaesthetics.
- History of abnormal bleeding tendencies/clotting disorders.
- History of glucose-6-phosphate dehydrogenase (G6PD) deficiency.
- History of significant neurological, hepatic, renal, endocrine, cardiovascular, cardiac arrhythmias, gastrointestinal, pulmonary, or metabolic disease.
- Regular use of anticoagulants.
- Received any investigational drug within 30 days or 5 half-lives of the investigational drug prior to study drug administration, and/or has planned administration of another investigational product or procedure during his/her participation in this study.
- Currently pregnant or nursing.
- The subject has a history of substance abuse or smoking, a positive ethanol breath test, urine cotinine, or urine drug screen at screening or at check-in. One repeat test is allowable if a false positive is suspected at the investigator's discretion.
- The subject has a positive serum hepatitis B surface antigen or positive HCV antibody test at the Screening Visit.
- Subject has a positive HIV test at the Screening Visit.
- Received bupivacaine, other local anaesthetic, prescription or OTC medications, herbal remedies or supplements per standard practice within 14 days of first study drug administration. Received caffeine and alcohol consumption within 48 h prior to drug administration.
- Any conditions, that according to investigator's best judgment, prevent participation in the trial.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description HYR-PB21 & Placebo HYR-PB21 - HYR-PB21 & Placebo Normal Saline - Liposome Bupivacaine & Placebo Liposomal bupivacaine - Liposome Bupivacaine & Placebo Normal Saline -
- Primary Outcome Measures
Name Time Method The area under the plasma concentration-versus-time curve from the time of administration to the time of the last quantifiable concentration calculated using the log-linear trapezoidal rule 15 days Pharmacokinetic parameters will be estimated from plasma bupivacaine measurements using non-compartmental analysis, based on the sampling schedule at predose (on Day 1 prior to study drug administration); 0.25, 0.5, 1, 2, 4, 8, 12, 18, 24, 30, 36, 48, 60, 72, 96, 120, 144, 168 hours and 14 days post-dose.
Investigator assessment of the ECG (normal, abnormal - not clinically significant, abnormal - clinically significant) 15 days 12-lead ECG will be obtained at screening, check-in，15-45 min pre-dose;0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 168 hours,and 14 days post-dose using an ECG machine for measurements of PR, QRS, QT, QTcF intervals,and heart rate.
The area under the plasma concentration-versus-time curve from the time of administration extrapolated to infinity. 15 days The residual area from the time of the last quantifiable concentration to infinity is to be calculated using the approximation
The maximum observed plasma bupivacaine concentration obtained directly from the experimental data without interpolation. 15 days The time to maximum plasma concentration (Cmax) 15 days The apparent terminal elimination half-life calculated as 0.693/λz 15 days The apparent terminal elimination rate constant determined by log-linear regression of the terminal log-linear segment of the plasma concentration-versus-time curve 15 days Observer's assessment of alertness/sedation(OAA/S) scale 5 days Six categories of responsiveness scores were characterized by the following responses for the OAA/S assessment:
* Responds readily to name spoken in normal tone (5 scores)
* Responds lethargically to name spoken in normal tone (4 scores)
* Responds only after name is called loudly, repeatedly, or both (3 scores)
* Responds only after mild prodding or shaking (2 scores)
* Responds only after painful trapezius squeeze (1 score)
* Does not respond to painful trapezius squeeze (0 score)The average Von Frey filament pressure across five test points at each protocol scheduled time-point 8 days Detection of the loss of feeling at injection site (at selected five representative test points) by Von Frey filaments in different pressures will be estimated at 15-45 min pre-dose; 0.25, 0.5 , 1, 2, 4, 8, 12, 18, 24, 30, 36, 48, 60, 72, 96, 120, 144, and 168 hour post-dose.
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 15 days
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
CMAX Clinical Research Pty Ltd
🇦🇺Adelaide, New South Wales, Australia